Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B1170000

Busulfan

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Busulfan, 1,4-Butanediol dimethanesulfonate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
CH3SO2O(CH2)4OSO2CH3
CAS Number:
55-98-1
Molecular Weight:
246.30
Beilstein:
1791786
MDL number:
MFCD00007562
UNSPSC Code:
41116107
PubChem Substance ID:
329773177
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

busulfan

manufacturer/tradename

EDQM

mp

114-117 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

InChI key

COVZYZSDYWQREU-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Busulfan EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301,H340,H350,H360FD

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1A - Muta. 1B - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Edward A Copelan et al.
Blood, 122(24), 3863-3870 (2013-09-26)
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant
Je-Hwan Lee et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(6), 701-709 (2012-11-07)
We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome. After randomization, 64 patients received busulfan (3.2 mg/kg per day × 4 days)
Christopher Bredeson et al.
Blood, 122(24), 3871-3878 (2013-10-02)
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025;
Arnon Nagler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-3556 (2013-08-28)
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a
Joel A Spencer et al.
Nature, 508(7495), 269-273 (2014-03-05)
Characterization of how the microenvironment, or niche, regulates stem cell activity is central to understanding stem cell biology and to developing strategies for the therapeutic manipulation of stem cells. Low oxygen tension (hypoxia) is commonly thought to be a shared
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service